Glaxo Group Limited

Glaxosmithkline LLC

Chun-wa Chung

Ian Kirby

Susannah Karen Ford

Ruth McAdam

Gary Peter Bembridge

Maria Feeney

Paul Bamborough

The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Antigen binding proteins to oncostatin M (OSM)

A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to: or and pharmaceutical compositions containing such compounds, and their use in therapy.

Process for the identification of a compound which inhibits the binding of the first bromodomain of each of human BRD-2, BRD-3, and BRD-4

Antigen binding proteins to Oncostatin M (OSM)

Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4

Growing community of inventors

Stevenage, United Kingdom

Chun-wa Chung